1,053
Participants
Start Date
March 22, 2022
Primary Completion Date
April 8, 2024
Study Completion Date
July 8, 2024
Empagliflozin/Linagliptin
Participants received Empagliflozin 10mg or 25mg and Linagliptin 5mg (Fixed Dose) Film-coated tablets orally once daily with or without food.
Samsung Internal medicine, Hanam
Brrunmadi Orthopedics, Seongnam-si
ST.Mary's Will Hospital, Seongnam-si
21Chospital, Seongnam-si
Seoul National University Bundang Hospital, Seongnam-si
Seo Jung Hwa Internal medicine, Gwangmyeong
Woori-hospital, Bucheon-si
IBS Medical Clinic, Incheon
Cheonan Chungmu Hospital, Cheonan-si
Daejeon Endo Internal Medicine, Daejeon
Yeongju gidok hospital, Yeongju
Dr.Yoon's Clinic, Gyeongsan-si
Yonsei Clinic, Busan
MyungJi Medical Center, Busan
Choi Won Rak Clinic, Busan
Choi Bongki Internal Medicine, Changwon-si
Gyeongsang National Univ. Changwon Hospital, Changwon-si
Seoul NIM Clinic, Changwon-si,
Chonnam National Univ. Hwasun Hospital, Hwasun-gun
Park Chang Hyun Clinic, Mokpo-si
Mokpo Gospel Internal Medicine Clinic, Mokpo-si
Park Il Jong Clinic, Mokpo-si
Yeosu Jeil Hospital, Yeosu
Good Morning Interanl medicine, Gwangju
Park Clinic, Gwangju
Dream Internal Medicine Clinic, Jeju City
D&F Hospital, Seoul
Kyung Hee University Medical Center, Seoul
Yonsei Checkup Clinic, Seoul
CBY Endocrine & Internal Medicine, Seoul
Lead Sponsor
Boehringer Ingelheim
INDUSTRY